EGFR and non-small cell lung carcinoma: Yang et al. summarized Lux-Lung series and indicated afatinib was active in NSCLC harboring certain types of uncommon EGFR mutations, especially G719X, S768I, and L861Q but was less active in those harboring other uncommon mutation types [15].